Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 28:11:1413825.
doi: 10.3389/fmed.2024.1413825. eCollection 2024.

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey

Goker Hakan  1 , Kelkitli Engin  2 , Karakulak Aladag Elifcan  1 , Demiroglu Haluk  1 , Turgut Mehmet  2 , Kambhampati Suman  3 , Krem Maxwell  3
Affiliations
Review

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey

Goker Hakan et al. Front Med (Lausanne). .

Abstract

The past decade has seen the development of immunotherapy for the treatment of multiple myeloma (MM), beginning with monoclonal antibodies (mAbs) in the relapsed and refractory setting and culminating in the market approval of chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs). The medical community is evaluating the efficacy and safety of these targeted immunotherapies, most of which currently target B-cell maturation antigen (BCMA) on the surface of plasma cells. Two anti-BCMA CAR-T products are available for treating relapsed or refractory MM: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Ide-cel and cilta-cel demonstrate the ability to induce deep responses in heavily pretreated diseases, including patients with triple-class-refractory and penta-refractory diseases. However, there are key similarities and differences regarding these agents, unknowns regarding their comparative efficacy and toxicity, and mechanisms underlying resistance to these new immunotherapies. This review discusses CAR-T cell therapy in relapsed refractory MM, with a focus on efficacy, toxicities, and the evolving trajectories of these therapies in the USA, as well as access in Turkey.

Keywords: B-cell maturation antigen; CAR-T cell; multiple myeloma; relapse; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. . Multiple myeloma. Nat Rev Dis Primers. (2017) 3:17046. doi: 10.1038/nrdp.2017.46 - DOI - PubMed
    1. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. . Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. (2017) 92:578–98. doi: 10.1016/j.mayocp.2017.01.003, PMID: - DOI - PMC - PubMed
    1. Goker H, Malkan UY, Demiroglu H, Buyukasik Y. Chimeric antigen receptor T cell treatment in hematologic malignancies. Transfus Apher Sci. (2016) 54:35–40. doi: 10.1016/j.transci.2016.01.011 - DOI - PubMed
    1. Munshi NC, Anderson LD, Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. . Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. (2021) 384:705–16. doi: 10.1056/NEJMoa2024850 - DOI - PubMed
    1. Bera TK. Anti-BCMA immunotoxins: design, production, and preclinical evaluation. Biomol Ther. (2020) 10:1387. doi: 10.3390/biom10101387, PMID: - DOI - PMC - PubMed

LinkOut - more resources